Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-31

Clinical Trial Update: Erbitux MEtastatic Colorectal Cancer Strategy Study [Phase 3]

View source ↗

Summary

Phase 3 trial update for Erbitux in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ERBITUX (cetuximab)

Snippet

Sponsor: Armando Orlandi | Conditions: Antineoplastic Agents | Phase 3 | Status: COMPLETED